Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

1.87
+0.06003.31%
Post-market: 1.880.0094+0.50%19:59 EDT
Volume:5.17M
Turnover:9.30M
Market Cap:374.37M
PE:-3.82
High:1.88
Open:1.81
Low:1.70
Close:1.81
52wk High:3.94
52wk Low:0.6925
Shares:200.20M
Float Shares:198.32M
Volume Ratio:0.89
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4900
EPS(LYR):-0.2764
ROE:97.76%
ROA:-7.17%
PB:-0.88
PE(LYR):-6.76

Loading ...

Company Profile

Company Name:
Esperion Therapeutics
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
304
Office Location:
3891 Ranchero Drive,Suite 150,Ann Arbor,Michigan,United States
Zip Code:
48108
Fax:
- -
Introduction:
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Directors

Name
Position
J. Martin Carroll
Chairman of the Board
Sheldon L. Koenig
Director, President and Chief Executive Officer
Jay P. Shepard
Independent Director
Robert E. Hoffman
Independent Director
Seth H.Z. Fischer
Independent Director
Stephen C. Rocamboli
Independent Director
Tracy M. Woody
Independent Director
Craig Thompson
Director

Shareholders

Name
Position
Sheldon L. Koenig
Director, President and Chief Executive Officer
Benjamin Halladay
Chief Financial Officer and Principal Accounting Officer
Benjamin O. Looker
General Counsel